Active Grants and Sponsored Research
Sponsoring Organization: Harvard Stem Cell Institute
Bone Marrow Spatial Transcriptomics to Enhance In Vitro Platelet Production from Stem Cell Sources
Description of Major GoalsThe major goal of this project is to validate results from bone marrow Multiplexed
Error-Robust Fluorescent In Situ Hybridization (MERFISH) identified megakaryocyte pathways and their ability to enhance in vitro platelet production from stem cell sources.
Error-Robust Fluorescent In Situ Hybridization (MERFISH) identified megakaryocyte pathways and their ability to enhance in vitro platelet production from stem cell sources.
Sponsoring Organization: RUNX1 Research Program and Alex's Lemonade Stand Foundation
Pharmacologic Enhancement of Residual Wild Type RUNX1 Activity in Familial Platelet Disorder with Propensity to Develop Leukemia (FPD/AML)
Description of Major GoalsThe goal of this study is test the use of src family kinase inhibitors in preclinical models for use in enhancing the residual wild type RUNX1 activity in patients with heterozygous loss-of-function RUNX1 mutations.
Sponsoring Organization: Elsa U Pardee]Foundation
Developing Novel Treatments for Juvenile Myelomonocytic Leukemia (JMML)
Description of Major GoalsThe major goal of this study is to test the efficacy of a small molecule inhibitor of CBFb-RUNX1 interactions for its ability reduce disease severity in a mouse model of juvenile myelomonocytic leukemia (JMML) as well as in JMML patient sample cellular assays.
Sponsoring Organization: National Institutes Of Health (NIH)
Regulation of RUNX1 Multiprotein Complex Formation during Hematopoiesis
Description of Major GoalsThe overall goal of this project is to further understand the mechanisms and signaling pathways that modulate RUNX1 protein-protein interactions during cellular differentiation.
Sponsoring Organization: Alex's Lemonade Stand Foundation
Transcriptional Effectors of Activated RAS Signaling in Juvenile Myelomonocytic Leukemia
Description of Major GoalsThe goal of this project is to test the role of RUNX1 as a dysregulated transcriptional effect target of activated RAS/Shp2 signaling in Juvenile Myelomonocytic Leukemia.